<DOC>
	<DOCNO>NCT02427568</DOCNO>
	<brief_summary>This small study design provide information whether MDMA-assisted psychotherapy safe helpful people anxiety relate life-threatening cancer neurological illness . The research see psychotherapy combine MDMA therapeutic setting ease anxiety face life threaten illness . Once enrolled study , people either receive two day-long psychotherapy session MDMA placebo , five people get placebo 13 get MDMA . Anxiety , depression , sleep quality , attitude toward death , posttraumatic growth , mindfulness , self-compassion , overall quality life measure start study two session . People close participant also complete questionnaire participant study mood behavior . Participants receive placebo enroll `` Stage 2 , '' receive three psychotherapy session MDMA , participant receive MDMA third MDMA-assisted experimental session . Anxiety symptom measure six 12 month participant 's final experimental session .</brief_summary>
	<brief_title>MDMA-assisted Psychotherapy Anxiety Associated With Life-threatening Illness</brief_title>
	<detailed_description>IIndividuals face , face , life-threatening illness contend physical symptom condition . Research suggest diagnosis , live life-threatening illness result symptom similar see Posttraumatic Stress Disorder ( PTSD ) . 3 , -4-methylenedioxymethamphetamine ( MDMA ) monoamine releaser unique pharmacological profile include decrease feeling fear , increase positive mood increase interpersonal trust . Findings clinical trial people PTSD anecdotal report suggest MDMA-assisted psychotherapy may assist people anxious result face life-threatening illness . This randomized , placebo-controlled pilot study MDMA-assisted psychotherapy 18 people anxiety stem life-threatening illness examines safety efficacy treatment . This study allow comparison impact placebo active dose MDMA-assisted psychotherapy anxiety , depression , sleep quality , global functioning , attitude toward death , posttraumatic growth , mindfulness , self-compassion , overall quality life . Participants must people either gender age 18 year old diagnose life-threatening cancer non-dementing neurological illness anxiety result confront illness . Eighteen participant enrol study . Five 18 participant receive placebo 13 receive MDMA . Therapy conduct male/female team , experienced therapist , others intern therapist supervision Principal Investigator . In first study segment , Stage 1 , participant two blind experimental session MDMA-assisted psychotherapy schedule two four week interval , within moderate course non-drug psychotherapy ( preparatory integrative session ) , complete primary endpoint assessment . After primary endpoint assessment , subject therapist unblinded fully debrief . Participants assign receive active dose MDMA receive third open-label experimental session active dose MDMA , complete Stage 1 . Participants assign receive placebo crossover , without complete Stage 1 , open-label study segment follow similar procedure , refer Stage 2 . Participants enrol group receive dose MDMA active dose Stage 1 , optional supplemental half dose , three experimental session time point equivalent Stage 1 . Anxiety , depression , sleep quality , attitude toward death , posttraumatic growth , mindfulness , self-compassion , overall quality life assess participant ' self-report baseline , primary endpoint , one month third experimental session Stage 1 , equivalent point Stage 2 . Additional assessment depression overall psychological functioning make blinded Independent Rater time point . A caregiver individual close relationship study subject also provide rating subject 's posttraumatic growth mood . Symptoms , long-term benefit , harm assess 6 month 12 month final experimental session . This study provide estimate effect size base response psychological symptom MDMA-assisted psychotherapy .</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>N-Methyl-3,4-methylenedioxyamphetamine</mesh_term>
	<criteria>Diagnosed lifethreatening cancer nondementing neurological illness , ongoing remission , possibility recurrence Prognosis least nine month life expectancy time screen Have anxiety result face illness Are least 18 year old Are willing refrain take psychiatric medication study period ; Are willing commit medication dosing , experimental session , followup session , complete evaluation instrument Are willing remain overnight study site experimental session integrative session occur next morning Must sign medical release investigator communicate directly therapist doctor ; Are willing select three observer complete observer measure subject attitude behavior Negative pregnancy test able bear child agree use effective birth control Are proficient speak read English Agree psychotherapy session record audio/video . Are pregnant nursing , woman child , practice effective mean birth control ; Weigh le 48 kg Are abuse illegal drug Are unable give adequate inform consent Upon review past , current drugs/medication must take medication exclusionary Upon review medical psychiatric history must current past diagnosis would consider risk participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Anxiety</keyword>
	<keyword>MDMA</keyword>
	<keyword>Life-threatening illness</keyword>
	<keyword>psychotherapy</keyword>
</DOC>